Publications by authors named "David F McDermott"

100Publications

Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.

Clin Genitourin Cancer 2020 06 5;18(3):179-184.e3. Epub 2019 Dec 5.

Division of Medical Oncology, Beth Israel Medical Center, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.11.016DOI Listing
June 2020

Checkpoint inhibitor immunotherapy in kidney cancer.

Nat Rev Urol 2020 03 4;17(3):137-150. Epub 2020 Feb 4.

Beth Israel Deaconess Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-020-0282-3DOI Listing
March 2020

Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma.

Immunotherapy 2020 01 29;12(1):37-51. Epub 2020 Jan 29.

Massachusetts General Hospital Cancer Center, Boston, MA 02214, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2019-0199DOI Listing
January 2020

Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma.

Cancer 2019 Dec 18;125(23):4148-4157. Epub 2019 Sep 18.

Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32361DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856361PMC
December 2019

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Oncologist 2019 06 29;24(6):725-727. Epub 2019 Apr 29.

Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0165DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656499PMC
June 2019

Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery.

J Clin Oncol 2018 Oct 29:JCO1801198. Epub 2018 Oct 29.

David F. McDermott, Dana-Farber/Harvard Cancer Center, Boston, MA; and Michael Carducci, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299339PMC
October 2018

Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.

Expert Opin Biol Ther 2018 09 30;18(9):947-957. Epub 2018 Aug 30.

b Biologic Therapy and Cutaneous Oncology Programs , Beth Israel Deaconess Medical Center , Boston , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2018.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2018.1513485DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289271PMC
September 2018

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.

Clin Genitourin Cancer 2018 10 25;16(5):341-348. Epub 2018 Apr 25.

Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175670PMC
October 2018

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med 2018 Apr 21;378(14):1277-1290. Epub 2018 Mar 21.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile; Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France; Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London; Aarhus University Hospital, Aarhus, Denmark (F.D.); Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.); British Columbia Cancer Agency, Vancouver, Canada (C.K.K.); Westmead Hospital and Macquarie University, Sydney (H.G.); Jena University Hospital, Jena, Germany (M.-O.G.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.); Niigata University, Niigata, Japan (Y.T.); Hospital Universitario 12 de Octubre, Madrid (D.C.); Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.); and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1712126
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1712126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972549PMC
April 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2018 06 14;36(17):1714-1768. Epub 2018 Feb 14.

Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center; Jennifer S. Mammen, Johns Hopkins University, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Alexander Spira, Virginia Cancer Specialists and US Oncology Research, Fairfax, VA; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center; Cristina A. Reichner, Georgetown University; Laura D. Porter, Colon Cancer Alliance; Washington, DC; Kelly J. Brassil, Aung Naing, Loretta J. Nastoupil, Maria E. Suarez-Almazor, and Yinghong Wang, MD Anderson Cancer Center, Houston, TX; Jeffrey M. Caterino, The Ohio State University Wexner Medical Center, Columbus, OH; Ian Chau, The Royal Marsden Hospital and Institute of Cancer Research, London and Surrey, United Kingdom; Marc S. Ernstoff and Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Bianca D. Santomasso and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center; Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Pamela Ginex, Oncology Nursing Society, Pittsburgh, PA; Jennifer M. Gardner, Seattle Cancer Care Alliance and University of Washington, Seattle, WA; Sigrun Hallmeyer, Oncology Specialists SC, Park Ridge, IL; Jennifer Holter Chakrabarty, University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; David F. McDermott, Beth Israel Deaconess Medical Center; Carole Seigel, Massachusetts General Hospital Cancer Center, Boston, MA; John A. Thompson, Seattle Cancer Care Alliance, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621PMC
June 2018

Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.

Clin Adv Hematol Oncol 2017 Jun;15(6):478-488

Beth Israel Deaconess Medical Center, and Dana-Farber/Harvard Cancer Center Kidney Cancer Program, Boston, Massachusetts.

View Article

Download full-text PDF

Source
June 2017

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

J Clin Oncol 2017 Dec 5;35(34):3851-3858. Epub 2017 Jul 5.

Hans J. Hammers, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; David F. McDermott, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Lionel D. Lewis, The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH; Martin H. Voss, Memorial Sloan Kettering Cancer Center, New York, NY; Padmanee Sharma, MD Anderson Cancer Center, University of Texas, Houston, TX; Sumanta K. Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Albiruni R. Abdul Razak, Princess Margaret Cancer Centre, Toronto, Ontario; Christian Kollmannsberger, British Columbia Cancer Agency, Vancouver, British Columbia; Daniel Y.C. Heng, Tom Baker Cancer Center, University of Calgary, Calgary; Jennifer Spratlin, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; M. Brent McHenry, Bristol-Myers Squibb, Princeton, NJ; and Asim Amin, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.72.1985
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.72.1985DOI Listing
December 2017

Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies.

J Oncol Pract 2017 09 31;13(9):e729-e737. Epub 2017 May 31.

Beth Israel Deaconess Medical Center; Boston College; and Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.020396DOI Listing
September 2017

Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era.

Cancer J 2017 Jan/Feb;23(1):63-67

From the *Beth Israel Deaconess Medical Center; †Dana-Farber Cancer Institute; and ‡Dana-Farber/Harvard Cancer Center, Boston; §Broad Institute of MIT and Harvard, Cambridge; and ∥Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000243DOI Listing
August 2017

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.

J Immunother 2017 01;40(1):31-35

*Vanderbilt University Medical Center, Nashville, TN †Beth Israel Deaconess Medical Center ‡Dana-Farber Cancer Institute §Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/immunotherapy-journal/2017/0100
Web Search
http://dx.doi.org/10.1097/CJI.0000000000000148DOI Listing
January 2017

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

J Clin Oncol 2016 Oct;34(30):3655-3663

Laurence Albiges, Wanling Xie, Rana R. McKay, Andre P. Fay, Guillermo de Velasco, Sabina Signoretti, and Toni K. Choueiri, Dana-Farber Cancer Institute; Wanling Xie, Rana R. McKay, Mark A. Preston, Eunyoung Cho, Sabina Signoretti, and Toni K. Choueiri, Brigham and Women's Hospital; Laurence Albiges, Wanling Xie, Rana R. McKay, Andre P. Fay, Guillermo de Velasco, Eunyoung Cho, David F. McDermott, Sabina Signoretti, and Toni K. Choueiri, Harvard Medical School; Mark A. Preston and Kathryn M. Wilson, Harvard School of Public Health; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Laurence Albiges, Gustave Roussy, Université Paris-Saclay, Villejuif, France; A. Ari Hakimi, Emily C. Zabor, Anders J. Skanderup, and Helena Furberg, Memorial Sloan Kettering Cancer Center, New York; Ronit Simantov and Xun Lin, Pfizer Oncology, New York, NY; Jae-Lyun Lee, University of Ulsan College of Medicine, Asan; Sun-Young Rha, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Sandy Srinivas, Stanford Cancer Institute, Stanford; Sumanta K. Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Georg A. Bjarnason, Sunnybrook Odette Cancer Center, Toronto; Scott Ernst, London Health Sciences Center, London, Ontario; Lori A. Wood, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia; Daniel Y.C. Heng, Tom Baker Cancer Center; University of Calgary, Calgary, Alberta, Canada; Ulka N. Vaishamayan, Karmanos Cancer Center, Detroit, MI; Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Takeshi Yuasa, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Aristotelis Bamias, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; and Eunyoung Cho, The Warren Alpert Medical School of Brown University; Brown University School of Public Health, Providence, RI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065111PMC
October 2016

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.

Clin Genitourin Cancer 2016 08 23;14(4):304-313.e6. Epub 2016 Feb 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.02.007DOI Listing
August 2016

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

J Clin Oncol 2016 Mar 11;34(8):833-42. Epub 2016 Jan 11.

David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Jeffrey A. Sosman, Vanderbilt University School of Medicine; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Mario Sznol, Yale Cancer Center, New Haven, CT; Christophe Massard, Gustave Roussy, Villejuif Cedex, France; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Omid Hamid, Angeles Clinic and Research Institute, Santa Monica; Marcella Fassò, Yan V. Wang, Wei Zou, Priti S. Hedge, and Gregg D. Fine, Genentech, South San Francisco, CA; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; and Thomas Powles, Barts Cancer Institute Centre for Experimental Cancer Medicine and the Royal Free National Health Service Trust, Queen Mary University of London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.7421DOI Listing
March 2016

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1803-13. Epub 2015 Sep 25.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; Institut Gustave Roussy, Villejuif (B.E.), and Bordeaux University Hospital, Hôpital Saint André, Bordeaux (A.R.) - both in France; Beth Israel Deaconess Medical Center (D.F.M.) and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.) - all in Boston; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.); Stanford Cancer Institute, Stanford, CA (S.S.); University of Washington and Fred Hutchinson Cancer Research Center, Seattle (S.S.T.); Vanderbilt University Medical Center, Nashville (J.A.S.); Fondazione Istituto Nazionale Tumori, Milan (G.P.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hospital Universitario 12 De Octubre, Madrid (D.C.); Westmead Hospital and Macquarie University, Sydney (H.G.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Helsinki University Central Hospital and University of Helsinki, Helsinki (P.B.); South West Wales Cancer Institute and Swansea University College of Medicine, Swansea (J.W.), and Royal Marsden Hospital, London (J.L.) - both in the United Kingdom; University Hospital Essen of University of Duisburg-Essen, Germany (T.C.G.); Chiba Cancer Center, Chiba (T.U.), and Niigata University, Niigata (Y.T.) - both in Japan; Hospital Sao Jose, Beneficencia Portuguesa de São Paulo, São Paulo (F.A.S.); British Columbia Cancer Agency, Vancouver, BC, Canada (C.K.); Bristol-Myers Squibb, Lawrenceville (J.S.S., I.M.W.) and Hopewell (L.-A.X.) - both in New Jersey; and M.D. Anderson Cancer Center, University of Texas, Houston (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719487PMC
November 2015

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.

Eur J Cancer 2015 Nov 4;51(17):2580-6. Epub 2015 Sep 4.

Kidney Cancer Center, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, United States; Kidney Cancer Program, Dana-Farber Harvard Cancer Center, Boston, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049150080
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2015.08.017DOI Listing
November 2015

Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.

J Am Coll Cardiol 2015 Sep;66(10):1160-78

Cardiovascular Division, Vanderbilt-Ingram Cancer Center, and Cardio-Oncology Program, Vanderbilt University School of Medicine, Nashville, Tennessee. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2015.07.025DOI Listing
September 2015

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Cancer 2015 Nov 11;121(22):4007-15. Epub 2015 Aug 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29622DOI Listing
November 2015

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

JAMA Oncol 2015 Jul;1(4):433-40

Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, New York9Weill-Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.1184DOI Listing
July 2015

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).

J Clin Oncol 2015 Jul 15;33(21):2384-91. Epub 2015 Jun 15.

Keith T. Flaherty, University of Pennsylvania, Philadelphia, PA; Judith B. Manola, Dana-Farber Cancer Institute; David F. McDermott and Michael B. Atkins, Beth Israel Deaconess Medical Center, Boston, MA; Michael Pins, Advocate Lutheran General Hospital, Park Ridge, IL; Janice J. Dutcher, Montefiore Medical Center, Bronx, NY; Daniel J. George, Duke University Medical Center, Durham, NC; Kim A. Margolin, Seattle Cancer Care Alliance, University of Washington, Seattle, WA; and Robert S. DiPaola, Cancer Institute of New Jersey at Hamilton, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.9727DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500832PMC
July 2015

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.

Cancer 2015 Oct 8;121(19):3435-43. Epub 2015 Jun 8.

Kidney Cancer Center, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29503DOI Listing
October 2015

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.

Cancer Immunol Res 2015 Oct 26;3(10):1158-64. Epub 2015 May 26.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Kidney Cancer Program, Dana-Farber Harvard Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596765PMC
October 2015

Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.

Am Soc Clin Oncol Educ Book 2015 :e291-7

From the Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e291DOI Listing
February 2016

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Jun 20;33(18):2004-12. Epub 2015 Apr 20.

Scott N. Gettinger and Mario Sznol, Yale Cancer Center, New Haven, CT; Leora Horn, David P. Carbone, and Jeffrey A. Sosman, Vanderbilt University Medical Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Leena Gandhi, David M. Jackman, and F. Stephen Hodi, Dana-Farber Cancer Institute; Rebecca S. Heist and Lecia V. Sequist, Massachusetts General Hospital Cancer Center; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Scott J. Antonia and Mary C. Pinder-Schenck, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Naiyer A. Rizvi, Richard D. Carvajal, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan, Ann Arbor, MI; Philip Leming, Christ Hospital Cancer Center, Cincinnati, OH; Suzanne L. Topalian, Drew M. Pardoll, and Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; and Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Georgia D. Kollia, and Ashok K. Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.3708
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.3708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672027PMC
June 2015

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Clin Ther 2015 Apr 29;37(4):764-82. Epub 2015 Mar 29.

Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2015.02.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497957PMC
April 2015

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

J Clin Oncol 2015 Jun 30;33(18):2013-20. Epub 2015 Mar 30.

David F. McDermott, Beth Israel Deaconess Medical Center; Toni K. Choueiri, Dana-Farber Cancer Institute/Brigham and Women's Hospital; Igor Puzanov and F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Charles G. Drake, Julie R. Brahmer, Hans J. Hammers, Suzanne L. Topalian, and Drew M. Pardoll, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Jon M. Wigginton, Georgia D. Kollia, Ashok Gupta, Dan McDonald, and Vindira Sankar, Bristol-Myers Squibb, Princeton, NJ; Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Nashville, TN; and Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517051PMC
June 2015

Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.

Clin Ther 2015 Apr 6;37(4):755-63. Epub 2015 Mar 6.

Division of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2015.02.003DOI Listing
April 2015

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).

J Pers Med 2014 Mar 7;4(1):52-64. Epub 2014 Mar 7.

Duke University Medical Center, 10 Bryan Searle Drive, Mudd Building, Rm 437, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://www.mdpi.com/2075-4426/4/1/52
Publisher Site
http://dx.doi.org/10.3390/jpm4010052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251407PMC
March 2014

Nivolumab for the treatment of cancer.

Expert Opin Investig Drugs 2015 Feb 12;24(2):253-60. Epub 2014 Dec 12.

Beth Israel Deaconess Medical Center , MASCO 428, 375 Longwood Ave Boston, MA 02215 , USA +1 617 632 9250 ; +1 617 632 9260 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2015.991819DOI Listing
February 2015

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

J Clin Oncol 2015 May 1;33(13):1430-7. Epub 2014 Dec 1.

Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York; Saby George, Roswell Park Cancer Institute, Buffalo, NY; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; David F. McDermott, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Bruce G. Redman, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ulka N. Vaishampayan, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Timothy M. Kuzel, Northwestern University Feinberg School of Medicine, Chicago, IL; Michael R. Harrison, Duke University Medical Center, Durham, NC; Harry A. Drabkin, Medical University of South Carolina, Charleston, SC; Theodore F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Kim A. Margolin, Stanford University, Stanford, CA; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Alexandre M. Lambert, Bristol-Myers Squibb, Braine-l'Alleud, Belgium; Ian M. Waxman, Bristol-Myers Squibb, Princeton, NJ; and Hans J. Hammers, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0703DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806782PMC
May 2015